It’s that one darn dog. The one in Hong Kong who tested “weak positive” for SARS-CoV-2 on February 28 . And again on February 29. And again on March 2 and yet again on March 5. He’s got people worried.
The situation with the coronavirus (COVID-19) is rapidly evolving as the virus is spreading in countries around the globe, including in the United States. This can make it challenging for your veterinary practice to know how to respond, and it’s important to revisit policies and procedures daily.
Experts have been predicting a fall surge in COVID cases since last spring, and now it's here. How will that impact hospitals?
The opioid shortage is both a manufacturing issue and a manufactured one. The manufacturing part can be traced back to production issues at a Pfizer Inc. plant in Kansas and residual damage from last year’s Hurricane Maria in Puerto Rico, a major pharmaceutical manufacturing center. The manufactured part can be traced back to the US Drug Enforcement Agency.
This week: A daring baboon breakout, Congress could ban Americans from eating their pets, and a cancerous mass that’s anything but.
As we kick off a new year, let’s take a look back at our top stories from 2021.
As 2019 draws to a close and we look back over the year that was, NEWStat put together a list of the most popular news stories we published over the last 12 months.
Catch up on the latest pet and veterinary news from the last week. In this update: Reporting animal abuse becomes mandatory in parts of Canada, a cloned dog gets cloned, and yes, dogs are smarter than cats.
This week: A frostbitten cat gets 3D-printed paws, a con man peddling canine-cancer cures gets caught, and a veterinary school that admits rejected candidates . . . for a price.
The opioid shortage isn’t going away any time soon. The shortage, which is severely affecting veterinarians’ ability to provide pain management for patients, is expected to last into 2019. The primary short-term cause is a production issue at a Pfizer, Inc. plant in Kansas, but residual hurricane damage in Puerto Rico, a major pharmaceutical manufacturing center, and a pre-existing Drug Enforcement Agency mandate to reduce the manufacture of opioid medication in the United States by 20% in 2018, are also having an effect.